Active Ingredient(s):Brigatinib FDA Approved: * April 28, 2017 Pharm Company: *ARIAD Category:Cancer
Brigatinib, sold under the brand name Alunbrig among others, is a small-molecule targeted cancer therapy being developed by Ariad Pharmaceuticals, Inc. Brigatinib acts as both an anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor.[medical citation needed]
Brigatinib could overcome resistance to osimertinib conferred by the EGFR C797S mutation if it is combined with an anti-EGFR antibody such as cetuximab or panitumumab.&am...
* May have multiple approval dates, manufacturers, or labelers.